Description

Zoladex (gozerelin) capsules for subcutaneous use 10.8 mg. №1 in the syringe applicator

Ingredients:

Zoladex contains 10.8 mg of gozerelin acetate as the active ingredient. Other ingredients include lactide/glycolide copolymer, D-mannitol, and carboxymethylcellulose sodium.

Dosage:

The recommended dosage of Zoladex is one 10.8 mg capsule administered subcutaneously every 28 days using the syringe applicator provided.

Indications:

Zoladex is indicated for the palliative treatment of advanced prostate cancer, endometriosis, and certain breast cancers.

Contraindications:

Do not use Zoladex if you are pregnant, breastfeeding, or allergic to gozerelin acetate or any other ingredients in the product.

Directions:

Administer Zoladex exactly as prescribed by your healthcare provider. Follow the instructions for subcutaneous injection carefully.

Scientific Evidence:

Studies have shown that Zoladex effectively suppresses the production of certain hormones, leading to tumor regression in hormone-sensitive cancers. Research published in the Journal of Clinical Oncology demonstrated the efficacy of Zoladex in improving survival rates in prostate cancer patients.

Additional Information:

It is important to store Zoladex in the refrigerator between 36°F to 46°F (2°C to 8°C) and protect it from light. Always consult your healthcare provider for personalized advice on using this medication.

Pharmacological Effects: Zoladex belongs to a class of medications known as gonadotropin-releasing hormone (GnRH) agonists. It works by continuously suppressing the production of certain hormones, thereby inhibiting the growth of hormone-sensitive tumors.

Clinical Trials: Clinical trials have demonstrated the efficacy of Zoladex in various conditions. A study published in the European Journal of Cancer evaluated the use of Zoladex in breast cancer treatment and reported positive outcomes in terms of tumor response and patient survival rates.